What Are the Fundamentals of Merck & Company (MRK)?

By Tamara Parker • Tuesday, December 05 17:20 • Permanent Link

Join us for a quick overview of Merck & Company, a Pharmaceutical company whose shares moved 1.1% today. Here are some facts about the stock that should help you see the bigger picture:

Merck & Company has moved -1.0% over the last year, and the S&P 500 logged a change of 17.0%
MRK has an average analyst rating of buy and is -14.95% away from its mean target price of $124.9 per share
Its trailing earnings per share (EPS) is $1.8
Merck & Company has a trailing 12 month Price to Earnings (P/E) ratio of 59.0 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $8.48 and its forward P/E ratio is 12.5
The company has a Price to Book (P/B) ratio of 6.53 in contrast to the S&P 500's average ratio of 2.95
Merck & Company is part of the Health Care sector, which has an average P/E ratio of 30.21 and an average P/B of 4.08
MRK has reported YOY quarterly earnings growth of 45.3% and gross profit margins of 0.7%
The company has a free cash flow of $5.68 Billion, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV, as well as a collaboration with Bionomics to identify novel a7 nAChR PAMs suitable for the treatment of cognitive disorder; and clinical trial collaboration and supply agreement with Ankyra Therapeutics to evaluate ANK-101 in combination with KEYTRUDA (pembrolizumab) in patients with advanced solid tumors, as well as a clinical trial collaboration and supply agreement with Phanes Therapeutics, Inc. to evaluate PT886 in combination with KEYTRUDA for the treatment of claudin 18.2 positive gastric or gastroesophageal junction adenocarcinomas, as well as a development and commercialization agreement with Daiichi Sankyo Company, Limited to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.